MicroRNAs in B cell lymphomas: How a complex biology gets more complex.
Brno, Czech Republic. In Leukemia, Jan 2015
We focus on miR-contribution to the regulation of important signalling pathways (like NF-κB, PI3K/AKT, TGF-β), BCR signalling and its modulators (like PTEN, SHIP-1, ZAP-70, GAB1, BTK), anti- and pro-apoptotic proteins (like BCL2, MCL1, TCL1, BIM, p53, SIRT1), and transcription factors (like MYC, MYB, PU.1, FOXP1, BCL6).
The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest.
Innsbruck, Austria. In Nat Commun, Dec 2014
Here we conduct a mini screen exploring systematically the contribution of individual BCL2 family proteins at single cell resolution to death on extended mitotic arrest, and demonstrate that the mitotic phosphorylation of BCL2 and BCLX represent a priming event for apoptosis that is ultimately triggered by NOXA-dependent MCL1 degradation, enabling BIM-dependent cell death.
Mcl-1 is a key regulator of the ovarian reserve.
Toronto, Canada. In Cell Death Dis, Dec 2014
The anti-apoptotic B-cell lymphoma 2 (Bcl-2) family member myeloid cell leukemia-1 (MCL-1) has a pro-survival role in various cell types; however, its contribution to oocyte survival is unconfirmed.
Anti-apoptotic BCL-2 family proteins in acute neural injury.
Dublin, Ireland. In Front Cell Neurosci, 2013
We discuss overlapping and differential effects of the individual family members BCL-2, BCL-extra long (BCL-XL), myeloid cell leukemia 1 (MCL-1), and BCL2-like 2 (BCL-W) in the control of survival during development and pathophysiological processes such as trophic factor withdrawal, ischemic injury, excitotoxicity, oxidative stress and energy stress.
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Milano, Italy. In Immunol Lett, 2013
The BCL2 family members play a central role in regulating programmed cell death (apoptosis) and arbitrating the cellular fate through an accurate balance between pro-apoptotic (BAX, BAK, and BH3-only proteins) and pro-survival (BCL2 and its closest homologues, BCLXL, BCLW and MCL-1) factors.
BH3 mimetics: status of the field and new developments.
More papers using
Paris, France. In Mol Cancer Ther, 2013
The prototype BH3 mimetic ABT-737 selectively targets the three prosurvival proteins BCL-XL, BCL-2, and BCL-W (but not MCL-1 or A1) and its oral derivative ABT-263 has proved promising in clinical trials.